Myriad acquiring Assurex

Molecular diagnostics company Myriad Genetics Inc. (NASDAQ:MYGN) is to acquire pharmacogenomics testing company Assurex Health Inc. (Mason, Ohio) for $225 million up front. Assurex shareholders are eligible for $185 million in milestones.

Assurex markets GeneSight, a genetic test to help healthcare providers select the appropriate psychotropic drugs for patients. Myriad said the acquisition will give it a neuroscience-focused commercial organization. ...